UCB Files Flurry of Patent Infringement Suits Over Epilepsy Drug

July 16, 2013
Germany’s UCB filed a whopping 15 patent infringement suits last week in a Delaware court to stave off generic drugmakers Sandoz, Glenmark, Watson and a dozen more from entering the market with copycats of its epilepsy treatment Vimpat, which loses marketing exclusivity in October.
Drug Industry Daily